Journal article
Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort
MC Gillies, RJ Walton, JJ Arnold, IL McAllister, JM Simpson, AP Hunyor, R Guymer, RW Essex, N Morlet, D Barthelmes
Ophthalmology | ELSEVIER SCIENCE INC | Published : 2014
Abstract
Objective To compare outcomes of intravitreal therapy from an observational study cohort with those of participants receiving treatment in the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab (MARINA) for the treatment of neovascular age-related macular degeneration (wet AMD). Design Database observational study. Participants in the observational cohort were chosen to match demographic features and entry criteria of the treatment group from MARINA. Outcomes over 12 months were compared. Participants Eight hundred twenty-one anti-vascular endothelial growth factor (anti-VEGF)-naïve eyes treated with ranibizumab with 12 months or more of follow-up were included in the total..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Supported by a grant from the Royal Australian and New Zealand College of Ophthalmologists Eye Foundation, Sydney (2007-2009); and the National Health and Medical Research Council, Canberra, Australia (grant no.: 2010-1012). Mark Gillies is a Sydney Medical Foundation Fellow and is supported by an National Health and Medical Research Council practitioner fellowship. Daniel Barthelmes was supported by the Walter and Gertrud Siegenthaler Foundation Zurich, Switzerland, and the Swiss National Foundation. Robyn Guymer is a National Health and Medical Research Council practitioner fellow.